Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized neoadjuvant carboplatin + olaparib versus taxane/anthracycline chemotherapy in HRD-positive triple-negative breast cancer
2016-004384-39Phase 2Active
- Sponsor
- Austrian Breast and Colorectal Cancer Study Group
- Start
- Nov 2018
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of olaparib, carboplatin, docetaxel, doxorubicin, cyclophosphamide and 1 more in triple-negative breast cancer (TNBC) (2 arms), sponsored by Austrian Breast and Colorectal Cancer Study Group. Primary endpoint: Residual cancer burden response. Started Nov 2018; status: active.
02
Drugs
olaparibcarboplatindocetaxeldoxorubicincyclophosphamide
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2016-004384-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004384-39.